CoChat
Sign Up
Cited by 727Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

Open access
Lindor, Keith D., Kowdley, Kris V., Heathcote, Jenny E., Harrison, Edwyn M., Jorgensen, Roberta, Angulo, Paul, Lymp, James F., Burgart, Lawrence, Colin, Patrick·2004·Hepatology
DOI 10.1002/hep.20092
Open this paper in CoChat — free accountOpen PDF

Abstract

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.20092

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 2

  1. Neuschwander-Tetri, 2002, Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPAR agonist rosiglitazone. abstract., HEPATOLOGY, 36, 379A
  2. Kobak, 2002, Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids., Gastroenterology, 122, A642

Cited by

Sorted by citations

Items 401–500 of 727

Related

See all

Metadata

Authors
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P.
Affiliations
  • Mayo Clinic (US)
  • University of Washington (US)
  • Toronto Western Hospital (CA)
  • Mayo Clinic in Arizona (US)
Corresponding author
Lindor, Keith D.
ORCID
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2004-03
Volume
39
Issue
3
Pages
770-778
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.20092
OpenAlex
W2139112405
Cited by
727
References
26
Citations by year
2026: 6 · 2025: 18 · 2024: 18 · 2023: 18 · 2022: 19 · 2021: 26 · 2020: 21 · 2019: 27 · 2018: 26 · 2017: 24 · 2016: 33 · 2015: 45 · 2014: 30 · 2013: 40 · 2012: 44
FWCI
35.12
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4201 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Baylor University
  • Baylor University Medical Center
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
ursodeoxycholic acid, nonalcoholic steatohepatitis, NASH treatment, liver histopathology, steatosis, necroinflammation, liver fibrosis, liver enzymes, placebo comparison, drug safety and tolerability
MeSH terms
Alanine Transaminase, Aspartate Aminotransferases, Cholagogues and Choleretics, Double-Blind Method, Fatty Liver, Fibrosis, Humans, Liver, Necrosis, Ursodeoxycholic Acid, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review